Biological Industries is now part of the Sartorius group. Click here for more


The Sartorius Group is a leading international partner of the biopharmaceutical industry and the research sector. We are helping biotech scientists and engineers across the entire globe to develop and manufacture medications from the first idea to production. So more people will have access to better medicine.

in 2019 sartorius acquired the majority stakes in Biological Industries, a cell culture media developer and manufacturer. These acquisition has significantly expanded our portfolio of cell and gene therapy, stem cell research and cell culture, allowing us to provide an industry-leading support service to our customers.

Biological Industries (BI) has 40 years’ experience in cell culture media development and manufacturing. Our products range from classical cell culture media to supplements and reagents for stem cell research and potential cell therapy applications to serum-free media and many other products for animal cell culture and molecular biology. We are committed to a culture of excellence through our advanced manufacturing and quality-control systems, superior regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training and R&D capabilities. 

Biological Industries Milestones


BI was founded in Kibbutz Beit Haemek, Israel as a division of a plant propagation laboratory with the purpose of supplying liquid media and supplement solutions for use in animal cell culture.


BI separates and is later incorporated as Biological Industries Israel Beit Haemek Ltd.  BI pioneer’s world leading serum-free media for animal cell culture and manufactures products for amniotic fluid testing.


The company sets its strategic growth plan and begins distribution throughout Europe and later to Asia.


BI launches new technology for the genetic diagnosis market, including growth media for chromosomal analysis at prenatal and later stages.


BI expands capabilities in the molecular biology market.


The company signs product distribution agreements and expands reach in over 33 countries including Japan, India, Taiwan and Korea.


BI announces successful completion of new state-of the-art cGMP facility for manufacturing, certified ISO 13485:2003 and ISO 9001:2008. The controlled environment clean rooms graded from ISO 8 up to ISO 5.


The company launches Custom Media Manufacturing services and expands product development capabilities providing great flexibility and custom formulations for large biotechnology and pharmaceutical companies.


BI launches NutriStem® - a leading, innovative, xeno-free human embryonic stem cell culture media developed in collaboration with Technion - Israel Institute of Technology.


The Board of Directors appoints Alon Ariel as CEO of Biological Industries. The company sets its strategic research and development plan to focus on expanding application development.


BI expands the NutriStem® brand to include a family of xeno-free products for human mesenchymal stem cells intended for use in cell therapy and research.


BI announces it has strengthened its distribution capacity by securing warehouse space in Europe.


The company expands manufacturing capabilities and distribution capacity in China, to serve cell culture market.

BI establishes Biological Industries USA, Inc. in Connecticut, a new division headquartered in the United States.


Corning, Biological Industries announce agreement for co-branded NutriStem® hPSC XF Medium.


Sartorius acquired a majority stake in Biological Industries and significantly expanded its cell culture media offering and complementing its product portfolio for customers in the dynamically growing advanced therapies market


A new and innovative xeno-free production facility for chemically defined products was opened in Beit Haemek, Israel